posted
Very nice. The news is all about stem cell. It should boost the whole sector imo. Thought it would do something for my NRGX for Parkinson’s and such. In time. Should speed things up considerably. These guys are trying to get (and somewhat succeeded) their name in the lime light to boost their research funding. Just poking their nose in the right places. Getting the word out that's for sure.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
.295 trying to break through... can it do it!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Nice finish. Short day Friday but could be exciting. Broke .3 Would have liked to see .31
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
break out yes or no? Not much volume but looking for .31 then maybe a breakout.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
imo they were sponging off someone elses news that was great for the sector but not immediatly great for ACTC - still years to go. Could see more on this next week.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
NEW YORK, Nov 27, 2007 (BUSINESS WIRE) -- The New York Society of Security Analysts (NYSSA) will present the 11th Annual Biotech/Specialty Pharma Conference on December 11-12, 2007.
The Nasdaq and AMEX biotech stock indexes have been consistently on the rise year over year. Small- and mid-cap companies have driven the growth, but big biotech has lagged behind big pharma. Although biotech has fallen behind most major indexes, some analysts believe that a turnaround is imminent. Leaders of small- and micro-cap companies will reveal plans to develop new drugs, diagnostics, and delivery technologies.
The following companies are presenting on day one:
BioSante Pharmaceuticals, Inc. (AMEX: BPA); DURECT Corporation (DRRX, Trade ); EntreMed, Inc. (ENMD, Trade ); GammaCan International, Inc. (GCAN, Trade ); Heska Corporation (HSKA, Trade ); Hollis-Eden Pharmaceuticals, Inc. (HEPH, Trade ); NovaBay Pharmaceuticals, Inc. (NBY, Trade ); and The Quigley Corporation (QGLY, Trade ).
The following companies are presenting on day two:
Advanced Cell Technology (ACTC, Trade ); Alseres Pharmaceuticals, Inc. (ALSE, Trade ); Cyclacel Pharmaceuticals, Inc. (CYCC, Trade ); Emergent BioSolutions, Inc. (EBS, Trade ); Hemispherx Biopharma, Inc. (HEB, Trade ); Immtech Pharmaceuticals, Inc. (IMM, Trade ); Neuralstem, Inc. (CUR, Trade ); Ortec International, Inc. (OTCI, Trade ); and Transdel Pharmaceuticals, Inc. (TDLP, Trade ).
The conference will be held on December 11, 2007, 8:30 a.m. to 4:40 p.m., and December 12, 2007, 8:30 a.m. to 4:10 p.m. at NYSSA, 1177 Avenue of the Americas, 2nd Floor, NYC. Registration deadline is December 4, one day, $265 NYSSA members, $365 nonmembers; two days, $365 NYSSA members, $465 nonmembers. No charge for press with credentials. A complete agenda is available at http://www.nyssa.org/Biotech2007 .
About NYSSA
The New York Society of Security Analysts (NYSSA) is celebrating 70 years as a leading forum for the investment community. NYSSA's mission is to promote best practices and the highest professional and ethical standards in the industry. NYSSA is the largest of the more than 135 societies worldwide that make up CFA Institute, which has more than 90,000 members.
SOURCE: The New York Society of Security Analysts
NYSSA Dawn Cavalieri, 646-871-3420 press*nyssa.org
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
NEW YORK, Nov 29, 2007 (BUSINESS WIRE) -- The New York Society of Security Analysts (NYSSA) will present the 11th Annual Biotech/Specialty Pharma Conference on December 11-12, 2007.
The Nasdaq and AMEX biotech stock indexes have been consistently on the rise year over year. Small- and mid-cap companies have driven the growth, but big biotech has lagged behind big pharma. Although biotech has fallen behind most major indexes, some analysts believe that a turnaround is imminent. Leaders of small- and micro-cap companies will reveal plans to develop new drugs, diagnostics, and delivery technologies.
New companies have been added to the agenda:
Chelsea Therapeutics (CHTP, Trade ); EpiCept Corporation (EPCT, Trade ); and YM BioSciences Inc. (YMI, Trade ).
The following companies are presenting on day one:
BioSante Pharmaceuticals, Inc. (BPAX, Trade ); Chelsea Therapeutics (CHTP, Trade ); DURECT Corporation (DRRX, Trade ); EntreMed, Inc. (ENMD, Trade ); Heska Corporation (HSKA, Trade ); Hollis-Eden Pharmaceuticals, Inc. (HEPH, Trade ); NovaBay Pharmaceuticals, Inc. (NBY, Trade ); The Quigley Corporation (QGLY, Trade ) and YM BioSciences Inc. (YMI, Trade ).
The following companies are presenting on day two:
Advanced Cell Technology (ACTC, Trade ); Alseres Pharmaceuticals, Inc. (ALSE, Trade ); Cyclacel Pharmaceuticals, Inc. (CYCC, Trade ); Emergent BioSolutions, Inc. (EBS, Trade ); EpiCept Corporation (EPCT, Trade ); Hemispherx Biopharma, Inc. (HEB, Trade ); Immtech Pharmaceuticals, Inc. (IMM, Trade ); Neuralstem, Inc. (CUR, Trade ); Ortec International, Inc. (OTCI, Trade ); and Transdel Pharmaceuticals, Inc. (TDLP, Trade ).
The conference will be held on December 11, 2007, 8:30 a.m. to 4:40 p.m., and December 12, 2007, 8:30 a.m. to 4:40 p.m. at NYSSA, 1177 Avenue of the Americas, 2nd Floor, NYC. Registration deadline is December 4, one day, $265 NYSSA members, $365 nonmembers; two days, $365 NYSSA members, $465 nonmembers. No charge for press with credentials.
The New York Society of Security Analysts (NYSSA) is celebrating 70 years as a leading forum for the investment community. NYSSA's mission is to promote best practices and the highest professional and ethical standards in the industry. NYSSA is the largest of the more than 135 societies worldwide that make up CFA Institute, which has more than 90,000 members.
SOURCE: The New York Society of Security Analysts
NYSSA Dawn Cavalieri, 646-871-3420 press*nyssa.org
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
Related Quotes Sym. Price Chg. ACTC Trade News 0.215 0.001 Advanced Cell Technology Seeking International Partners for Its Therapeutic Programs
Dec 6, 2007 08:00:09 (ET)
LOS ANGELES, Dec 06, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that it is seeking international partners for each of its three lead therapeutic programs, including its Myoblast program for treating heart failure, its Retinal Pigment Epithelium program for treating degenerative retinal disease, and the Hemangioblast program for the treatment of blood and cardiovascular indications. The company is making significant progress in the development of each of these therapeutic programs within the United States.
Advanced Cell Technology has made a strategic decision to seek partners for each of these programs internationally, including regions such as Europe, the Middle East and Asia, as the company recognizes that there is strong interest in the field of stem cells worldwide. ACT has asked Burrill & Company, which it hired last year to advise on a number of strategic initiatives, to renew its focus on seeking international partners. Interested parties worldwide should contact Mr. William Caldwell, IV, Chairman and CEO of Advanced Cell Technology at 310-481-5124.
"We recognize that there is material interest in the stem cell and regenerative medicine field globally and will seek strong partners from the worldwide medical community to pursue our programs outside of the United States and complement the work we are doing at home. We are very pleased to continue our successful relationship with Burrill & Company and utilize their extensive global network to further these discussions," said Mr. William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Advanced Cell Technology to Present at 11th Annual New York Society of Security Analysts Biotech/Specialty Pharma Conference on Wednesday, December 12th
Dec 12, 2007 08:01:03 (ET)
LOS ANGELES, Dec 12, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that the Company will present at the 11th Annual Biotech/Specialty Pharma Conference hosted by the New York Society of Security Analysts (NYSSA) taking place on Tuesday and Wednesday, December 11 and 12, 2007. The conference will be held at the NYSSA headquarters located at 1177 Avenue of the Americas in New York City.
Advanced Cell Technology's presentation will take place on Wednesday, December 12 at 12:45 p.m.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
11th Annual Biotech/Specialty Pharma Conference DATE December 11-12, 2007
TIME Day 1 — 8:30 a.m.-4:40 p.m. Day 2 — 8:30 a.m.-3:15 p.m.
CHAIRS Sherry Lombardi, The Answer Factory Laurie Malen, The Answer Factory
LOCATION NYSSA 1177 Avenue of the Americas, 2nd Floor (between 45th and 46th Streets), NYC (Directions) Photo ID required for access to the building.
REGISTER/FEE Early Registration by November 27 One Day: Members $195 | Nonmembers $295 Two Days: Members $295 | Nonmembers $395 Registration November 28 to December 4 One Day: Members $265 | Nonmembers $365 Two Days: Members $365 | Nonmembers $465 After December 4 Register at the door: Additional $50 due (space permitting)
CREDIT PD/CE/CPE = 2
-------------------------------------------------------------------------------- Register Online Register via Mail/Fax Policies & Procedures
CONFERENCE DESCRIPTION The Nasdaq and AMEX biotech stock indexes have been on the rise during the last few years. Both hit record highs in Q2, only to give back some of their gains over the summer. Small- and mid-cap companies have driven the growth, while big biotech has lagged behind big pharma. The volume of biotech IPOs also continues to grow, up over 31% in 2006 from 2005. After-market returns of those offerings increased to an average of 40% versus 7% in the prior year.
In general, however, biotech has lagged behind most major indexes over the last year. Biotech stocks as a group have trailed the S&P 500 by more than 18 percentage points. Still, many analysts believe that the group is poised for a turnaround, considering the aging population that will continue to drive demand and innovation.
Don’t miss this chance to learn about the opportunities with specialty pharmaceutical and biotechnology stocks. The CEOs, CFOs, and other VIPs from many of the industry’s most innovative small- and micro-cap companies will discuss their plans to invent, develop, research, and market important new drugs, diagnostics, and delivery technologies.
AGENDA Day 1 8:30 Check-in & Continental Breakfast 8:55 Welcome & Introductory Remarks 9:00 Outlook for the Biotech and Specialty Pharma Industry George Fulop, MD, Managing Director, Stuyvesant Capital Management
9:35 Chelsea Therapeutics (Nasdaq: CHTP) Keith Schmidt, VP of Marketing and Sales Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases.
10:10 Break 10:20 DURECT Corporation (Nasdaq: DRRX) Matthew Hogan, CFO DURECT is an emerging specialty pharmaceutical company developing pharmaceutical systems based on its proprietary drug delivery platform technologies. 10:55 The Quigley Corporation (Nasdaq: QGLY) Guy Quigley, Chairman, President, and CEO Quigley is a diversified natural health life science company.
11:30 BioSante Pharmaceuticals, Inc. (Nasdaq: BPAX) Stephen M. Simes, President and CEO BioSante Pharmaceuticals is developing a pipeline of hormone therapy products to treat both men and women.
12:00 Lunch
12:15 Luncheon Presentation Public Relations: Eight Simple Rules for Achieving Maximum Value for Your Company, Your Fund, or Yourself Dian Griesel, President and CEO, The Investor Relations Group 1:00 YM BioSciences Inc. (AMEX: YMI) Sean Thompson, VP, Corporate Development YM BioSciences is an oncology company that identifies, develops, and commercializes differentiated products for patients worldwide.
1:35 EntreMed, Inc. (Nasdaq: ENMD) James S. Burns, President and CEO EntreMed is a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammation.
2:10 Heska Corporation (Nasdaq: HSKA) Robert Grieve, Chairman and CEO Heska sells advanced veterinary diagnostic and other specialty veterinary products. 2:45 Break
2:55 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) Richard B. Hollis, Chairman and CEO Hollis-Eden Pharmaceuticals is a world leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals for human health. 3:30 NovaBay Pharmaceuticals, Inc (AMEX: NBY) Jack O’Reilly, SVP, Corporate Development and CFO NovaBay Pharmaceuticals is developing nonantibiotic antimicrobial products for multiple indication with partnerships with leading companies.
4:05 Immtech Pharmaceuticals, Inc. (AMEX: IMM) Eric L. Sorkin, Chairman and CEO Immtech Pharmaceuticals is developing therapies to treat and prevent serious infectious diseases.
4:40 Closing Remarks & Adjournment
AGENDA Day 2 8:30 Check-in & Continental Breakfast 8:55 Welcome & Opening Remarks 9:00 Changing Investor Demands in the Specialty Pharmaceutical Sector Angela Larson, Susquehanna Financial Group
9:35 Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) Spiro Rombotis, President and CEO Cyclacel Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.
10:10 Break
10:20 EpiCept Corporation (Nasdaq: EPCT) Jack Talley, CEO Epicept is a specialty pharmaceutical company focused on the development of pharmaceutical products for the treatment of cancer and pain.
10:55 Emergent BioSolutions, Inc. (NYSE: EBS) Robert G. Burrows, VP, Investor Relations Emergent BioSolutions is a profitable biopharmaceutical company with growing revenues that fund advanced and follow-on development pipelines addressing large markets. The company develops, manufactures, and commercializes immunobiotics consisting of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease.
11:30 Hemispherx Biopharma, Inc. (AMEX: HEB) Anthony Bonelli, President and COO Hemispherx Biopharma is an advanced biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders.
12:00 Lunch
12:45 Advanced Cell Technology (OTCBB: ACTC) William M. Caldwell, IV, Chairman and CEO Ivan Wolkind, SVP, Finance/Administration and Chief Accounting Officer Advanced Cell Technology is a leading biotechnology company in the field of regenerative medicine. 1:20 Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) Kenneth L. Rice Jr., EVP and CFO Alseres Pharmaceuticals is developing groundbreaking regenerative therapeutics for devastating conditions such as spinal cord injury.
1:55 Break 2:05 Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) Juliet Singh, PhD, President and CEO Transdel Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of noninvasive, topically targeted medications. 2:40 Ortec International, Inc. (OTCBB: OTCI) Costa Papastephanou, PhD, CEO Ortec International is a company focused on advancing regenerative medicine through the development of cellular technology and advanced biomaterial products.
3:15 Closing Remarks & Adjournment
NYSSA reserves the right to change any part of its published program or list of presenters due to unforeseen circumstances.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Related Quotes Sym. Price Chg. ACTC Trade News 0.16 -0.015 Advanced Cell Technology Issues Letter to Investors
Dec 19, 2007 11:53:01 (ET)
LOS ANGELES, Dec 19, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that it has issued a letter to its investors from William M. Caldwell, IV, Chairman and CEO, updating the company's progress year-to-date. The text of the letter is available on the company's website at www.advancedcell.com and is included in this press release below:
Dear Stockholders,
As we move through 2007's holiday season and approach year end, I wanted to update all of you about the events that took place for our company this year. 2007 has been a year of significant scientific accomplishment and positive transformation for Advanced Cell Technology as well as one of great change for the regenerative medicine industry. I have broken this letter into four components. First and foremost, I would like to discuss our research, development, and clinical progress, as this is clearly the most important facet of our company. Second, I will discuss Advanced Cell Technology's transformation from a research and development organization into a biotechnology company with novel therapies in clinical trials for currently difficult or impossible to treat indications. Third, I will outline our interpretation of the state of the stem cell industry. And finally, I will discuss what our hopes and expectations are for 2008 and beyond.
Scientific Progress
Advanced Cell Technology has three primary therapeutic programs:
1) our Myoblast Program, an autologous adult stem cell therapy for the treatment of heart failure;
2) our Retinal Pigmented Epithelial (or RPE) cell Program, an embryonic stem cell therapy for the treatment of degenerative retinal disorders; and
3) our Hemangioblast (or HG) cell Program, an embryonic stem cell therapy for the treatment of blood and cardiovascular indications.
We have made progress in each of these programs this year and will exit 2007 with the Myoblast Program preparing to enter Phase II human clinical trials and our RPE and HG Programs in preclinical trials. In addition, our company has a number of proprietary technology platforms, including our single cell biopsy technique for creating embryonic stem cell lines without destroying embryos.
Myoblast Program
Milestones:
-- Acquired Mytogen, Inc., and its Myoblast therapy for the treatment of heart failure. Therapy successfully completed Phase I human clinical trials.
-- Presented 6-month data at TCT 2007 demonstrating safety and improvement in heart failure measures.
-- Presented 12-month data at the AHA's 2007 conference in Orlando demonstrating safety and persistence of therapeutic effect over an extended period of time.
-- Entered into a letter of intent with Catholic Healthcare West for a proposed exclusive business arrangement to establish a clinical trial research site and a North American regenerative medicine interventional cardiology training center for our Phase II Myoblast clinical trial.
-- Pursuing international partnerships for Phase II human clinical trials.
-- On schedule to begin Phase II human clinical trials at eight sites shortly.
We acquired our Myoblast Program in connection with our acquisition of privately-held Mytogen, Inc., which closed in September 2007. The myoblast therapy involves transplantation of expanded autologous myoblasts derived from a small biopsy of skeletal muscle from a patient's leg. The myoblasts are expanded into hundreds of millions of cells over a period of three weeks and then transplanted back into the patient's scarred heart tissue via a catheter-based procedure. The Myoblast Program to date has successfully completed four Phase I human clinical trials utilizing the therapy safely in over 40 patients. While the successful Phase I human clinical trials were focused on the safety of the therapy, the clinical data from those trials suggested that the myoblasts can improve heart function that leads to an improved quality of life for the patient.
In October and November of this year, Dr. Nabil Dib, one of the principal investigators for our Myoblast Program, presented 6-month and 12-month data for the program at TCT 2007, a leading interventional cardiology conference, and at the American Heart Association's annual meeting in Orlando, Florida, respectively. The two sets of data: 1) demonstrated myoblast safety with no evidence for increased risk of arrhythmia; 2) distinguished the ACT Myoblast Program as the leader in the industry as it is the only program not required to use anti-arrhythmia medications and/or an implanted defibrillator device; 3) showed that the effects of ACT's myoblast therapy persisted for an extended period of time, an effect that has not been demonstrated by any other cellular therapy for heart disease; 4) provided evidence that the hearts of the patients that received the therapy showed less cardiac remodeling in comparison to controls, remodeling being a progressive enlargement of the heart that signifies worsening of function; and 5) that by using the ACT technology doctors have for the first time the opportunity to successfully replace scarred heart tissue with healthy muscle via intracardiac injections of autologous skeletal myoblasts.
We are on schedule to begin the Phase II human clinical trial for the treatment of heart failure in approximately 160 patients. In that light, we entered into a letter of intent with Catholic Healthcare West, America's eighth largest hospital system, for a proposed exclusive business arrangement to establish a clinical trial research site and a North American regenerative medicine interventional cardiology training center for our Phase II Myoblast clinical trial. In addition, we are actively pursuing international partnerships to investigate our Myoblast Program and to commence international Phase II human clinical trials for the novel therapy. If the Phase II trials prove successful, we will proceed with a pivotal Phase III trial.
According to the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), approximately 5 million people in the United States have congestive heart failure (CHF) and an estimated 400,000 new cases are diagnosed each year. Roughly 50% of CHF patients die within 5 years. The annual number of deaths directly from CHF increased from 10,000 in 1968 to 42,000 in 1993, with another 219,000 related to the condition. CHF is the first-listed diagnosis in 875,000 hospitalizations, and the most common diagnosis in hospital patients 65 years and older. Consequently, we are excited by both the market opportunity for our Myoblast Program as well as the potential to help the growing number of patients suffering from heart failure in the United States and abroad.
Retinal Pigmented Epithelial (RPE) Program
Milestones:
-- Demonstrated visual function rescue in Royal College of Surgeons (RCS) rats in 2006.
-- Entered into a research services agreement with the Casey Eye Institute at OHSU for preclinical studies.
-- Published OHSU dosage study results demonstrating a statistically significant positive therapeutic effect.
-- Began preliminary discussions with the FDA to initiate clinical studies.
-- Contracted with a leading contract research organization for an extensive preclinical program.
-- MPI Research initiated pilot studies under Good Laboratory Practices (GLP).
-- Provided we receive positive feedback from the FDA, plan to file IND in 2008.
Studies of our proprietary RPE cells have shown that the therapy may ultimately provide effective treatment of degenerative retinal disorders, including macular degeneration, which represents a $28 billion dollar market. Age-related macular degeneration (AMD) affects more than 30 million people worldwide and is the leading cause of blindness in people over 60 in the United States. The prevalence of AMD begins to increase after the age of 50. Approximately 15% of people over 75 have the condition. To date, AMD patients have had few if any effective therapies for treatment; thus, the need for novel therapies that we are developing is clear.
In 2006, we demonstrated visual function rescue in rat models using our RPE therapy. In February of this year, we entered into a research services agreement with Oregon Health and Science University (OHSU). Under the terms of the research agreement, we have been collaborating with Dr. Raymond Lund, Dr. Richard Weleber, and Dr. Peter Francis at the Casey Eye Institute at OHSU to conduct preclinical studies for the program. Specifically, the research team has been conducting dosage studies utilizing our RPE cells in the RCS rat model and plans to conduct similar studies in other rodent models of retinal degenerative disease. We are also in discussions with the OHSU team regarding future plans for a Phase I human clinical trial.
In November of this year at Neuroscience 2007, researchers at OHSU presented results of the study, which used ACT RPE cells that were manufactured under GMP compliant conditions (21CFR211) at our facility in Worcester, Massachusetts. The RPE cells were thoroughly characterized and cryo-preserved and shipped to researchers at OHSU for transplantation. The transplanted rats were given a range of doses of the RPE cells and monitored and evaluated at multiple time points. The results of the study showed that the RPE cells demonstrated a statistically significant therapeutic effect compared to controls with a maximum efficacious effect at an intermediate dose level. Histological assessment showed integration of the human RPE cells into the rodent's RPE layer without migration into the retina. The conclusions drawn by researchers were that visual function can be rescued and preserved in this animal model of disease utilizing GMP-compliant human ES-derived RPE cells with a functional dose threshold and that these cells may provide an effective donor cell source to rescue photoreceptors in conditions like AMD, where RPE function is compromised. We plan to present this data to the FDA when we file an IND for the therapy.
As we move closer to filing an IND for our RPE therapy, we decided to initiate preliminary discussions with staff from the Office of Cellular, Tissue, and Gene Therapies within the Center for Biologics Evaluation and Research at FDA. These discussions took place earlier this year. In addition, we contracted with a leading contract research organization to begin work on an extensive preclinical program. Furthermore, MPI Research, located in Mattawan, Michigan, initiated pilot studies under Good Laboratory Practices (GLP) for the ongoing RPE Program. We are hopeful that we can file an IND for the RPE therapy next year and begin human clinical trials soon thereafter.
Hemangioblast (HG) Program
Milestones:
-- Published research in Nature Methods demonstrating HG cells' ability to repair vascular damage in animals.
-- Seeking international partnerships for preclinical and clinical trials.
-- Targeting IND filing in 2008.
We continue to investigate the possibility of using our proprietary hemangioblast cells to treat blood and cardiovascular diseases, stroke and cancer. In May of this year, research conducted by our team of scientists and our collaborators from the University of Florida at Gainesville and the Memorial Sloan-Kettering Cancer Center in New York City was published in the journal Nature Methods. The research described an efficient method for generating large numbers of hemangioblasts derived from human embryonic stem cells that were capable of differentiating into blood vessels as well as into all blood and immune cell lineages. When the cells were injected into animals that had retinal damage from diabetes or ischemia-reperfusion injury (lack of adequate blood flow) of the retina, the cells homed to the site of injury and showed robust reparative function of the entire damaged vasculature within 24 to 48 hours. The cells showed a similar regenerative capacity in animal models of both myocardial infarction (50% reduction in mortality rate) and hind limb ischemia, with restoration of blood flow to near normal levels.
We are actively seeking international partnerships for our HG Program to assist with our preclinical research and, ultimately, human clinical trials. We are hopeful that we can file an IND next year for the program and move forward with human clinical trials.
Single Cell Biopsy Embryonic Stem Cell Development Technique
Milestones:
-- Last year we described our proprietary single cell biopsy technique for creating human embryonic stem cell lines without damaging embryos.
-- Announced the creation of the first human embryonic stem cell line without destroying an embryo this year, quelling much of the initial controversy.
-- The NIH is considering our single cell biopsy technique for federal funding.
Our single cell biopsy technique for creating human embryonic stem cell lines without damaging embryos continues to attract a significant amount of attention. Recall that in August of last year we announced that our scientists had published a paper in the journal Nature explaining how they had generated human embryonic stem cells using this approach. The method derives the cells from human blastomeres with a single-cell biopsy technique called Preimplantation Genetic Diagnosis (PGD). This technique is used by in vitro fertilization clinics to assess the genetic health of preimplantation embryos. The cell lines produced using this technique appeared to be identical to human embryonic stem cell lines derived from later stage embryos using techniques that destroy the embryo's developmental potential. A significant amount of controversy ensued after our announcement challenging the validity of the results, but we were pleased to report in June of this year that we had successfully produced a human embryonic stem cell line without destroying an embryo at our lab in Worcester, Massachusetts. Dr. Robert Lanza, M.D., our Chief Scientific Officer, definitively announced that he and his team had reproduced the work of removing a single cell blastomere from a human embryo with the surviving embryo cryo-preserved, quelling much of the initial controversy.
The technique is also beginning to attract the attention of our federal government. In June of this year, President Bush issued an Executive Order requiring that "The Secretary of Health and Human Services ... conduct and support research on the isolation, derivation, production, and testing of stem cells that are capable of producing all or almost all of the cell types of the developing body and may result in improved understanding of or treatments for diseases and other adverse health conditions, but are derived without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo or fetus." Roughly three months later, the NIH announced that it would begin implementing President Bush's Executive Order. Our single cell biopsy technique was cited by the NIH as an alternative method in its implementation plan. The NIH plan calls for "aggressively pursuing an assessment of the potential of alternative sources of pluripotent stem cell lines, including altered nuclear transfer; single cell embryo biopsy, and reprogramming, or dedifferentiation of somatic cells, such as skin cells."
We believe our single cell blastomere technology directly addresses the President's ethical concerns and, unlike the other potential solutions described in the order, is available today. We are encouraged by the NIH's willingness to explore ways to increase the federally approved stem cell lines available and hope they will consider our technique for federal funding. We believe that such consideration reflects the will of the American people to bring novel therapies derived from stem cell research to patients with few or no alternatives.
The Transformation of Advanced Cell Technology
Milestones:
-- Acquired Mytogen and transformed from a development stage to a clinical stage company.
-- Solidified our management team by naming Dr. Lanza Chief Scientific Officer, Dr. Dinsmore Senior VP - Clinical and Regulatory, and Ivan Wolkind Senior VP - Finance, Administration and Chief Accounting Officer.
-- Improved our patent portfolio to 380 owned or licensed patents and patent applications.
-- Received and/or participated in grants from the NIH and CIRM.
-- Raised $10 million in gross proceeds from the private placement of senior secured convertible debentures.
Earlier this year, our company was presented with a unique opportunity that culminated in a merger with Mytogen, Inc. We entered into a letter of intent to acquire Mytogen in May, signed a definitive merger agreement in July, and closed the acquisition in September. The Mytogen transaction was transformational for Advanced Cell Technology for several reasons. First, Mytogen helped us broaden our regenerative medicine technology platform from exclusively focused on embryonic stem cell therapies to research programs and therapies based on both embryonic and adult stem cell technology. This technology platform expansion has allowed us to not only investigate more new therapies for a larger set of indications, but it has also provided access to opportunities largely unavailable to companies focused exclusively on embryonic stem cell science. Second, what with the Myoblast Program having successfully completed Phase I human clinical trials and poised to begin Phase II human clinical trials shortly, the Mytogen acquisition immediately transformed ACT from a development stage to a clinical stage company.
With the merger closed and the Mytogen team fully integrated into the Advanced Cell Technology family, we solidified our management team. While I remain Chairman and CEO, we named Dr. Robert Lanza, M.D., our Chief Scientific Officer; Dr. Jonathan Dinsmore, Ph.D., our Senior VP - Regulatory and Clinical; and Ivan Wolkind our Senior VP - Finance, Administration & Chief Accounting Officer. Dr. Lanza has over 25 years of relevant research and industrial experience, including his position as Director of Transplantation Biology at BioHybrid Technologies, Inc. He is currently an Adjunct Professor at the Institute for Regenerative Medicine, Wake Forest University School of Medicine, and has several hundred scientific publications and patents and has authored and/or edited 16 books. Dr. Dinsmore was formerly responsible for all aspects of Mytogen's cell production operations, basic science program, and research and development efforts, and directed both clinical and preclinical research programs at Diacrin and GenVec. Mr. Wolkind joined ACT in March 2005 after serving as the Executive Vice President of Finance and CFO for Eyematic. Mr. Wolkind previously held senior financial positions at a number of large companies and worked in the financial services and banking audit group at KPMG.
Our corporate transformation also allowed us to consolidate and improve our patent portfolio. In February, we acquired the intellectual property assets of Infigen, Inc. relating to parthenogenesis, oocyte activation and other related technologies. We acquired a total of 26 issued patents and numerous pending patent applications for a combination of cash and shares of common stock. Three months later in May we announced an expanded, non-exclusive commercialization agreement with Wisconsin Alumni Research Foundation (WARF) that granted us rights to the commercial use of human embryonic stem cells to develop human therapies (with the exception of neuronal, pancreatic beta cells, and cardiac applications) and enabled the marketing of a broad array of research products. The agreement granted us commercial access to an additional 150 important stem cell technology patents and patent applications. As a result of the Infigen, WARF, and Mytogen deals, we now own or license over 380 patents and patent applications.
2007 was another challenging year for financing companies in our space, what with difficult public markets (especially in biotechnology) and the ban on federal funding for many areas of stem cell research. Nevertheless, we successfully exploited a handful of alternative financing opportunities. In January, our company was awarded a research grant from the NIH in conjunction with a research project currently underway with The Burnham Institute of Medical Research, one of our academic partners. The grant, titled "Directed Differentiation of Embryonic Stem Cells using Phage Displayed Ligands," further funds research by ACT and The Burnham Institute aimed at obtaining specialized cells of therapeutic interest from human embryonic stem cells using NIH-approved stem cell lines. Furthermore, as the $3 billion in funding to be distributed by CIRM (the California Institute for Regenerative Medicine) over 10 years from California's Proposition 71 begins to trickle out, we have seen some early positive developments including the use of ACT's human embryonic stem cells in a study to determine if the cells are safe and effective in animal models for heart attacks and heart failure.
Our most substantial capital raise this year came from the completion of a private placement of senior secured convertible debentures that closed in August resulting in gross proceeds of $10 million. The cash infusion provided us with capital necessary to continue our promising research and development platforms and has brought us closer to both additional clinical trials and, ultimately, to commercializing our therapies in the marketplace.
The State of the Stem Cell Industry
Politics
The legislative environment for stem cell research is complex and largely misunderstood; consequently, I'd like to outline for you the facts as well as how we see the legislative landscape unfolding going forward. In August 2001, President Bush enacted a ban on federal funding for deriving new embryonic stem cells from fertilized embryos. This does not mean that embryonic stem cell research is "illegal," rather that federally collected tax dollars cannot be used to fund the research. Unfortunately, however, because of the federal funding ban, research institutions (be they public, private, academic, etc.) have been forced to build entirely "clean" facilities to be used exclusively for such research. This has resulted in a significant (financial) barrier to research progress. Furthermore, while President Bush did allow research to continue on the embryonic stem cell lines existing at that time - often referred to as the "Presidential Lines" - (unbeknownst to the President) the lines are contaminated and largely unusable. Despite the challenging environment, we, as a company, have made the progress I've outlined in this letter.
Still, there have been a number of initiatives aimed at improving the landscape to further research in this field at both the federal and state levels. In July 2006, the Senate voted 63-37 in favor of a bill that passed in the House of Representatives to lift the ban on federal funding of stem cell research, but the bill did not have enough support to override the President's inevitable veto. In January and April of this year, the House and the Senate, respectively, passed the Stem Cell Research Enhancement Act of 2007. Once again, however, in each vote the bill came just a few "ayes" shy of a veto-proof majority. Despite these (largely expected) legislative defeats, we believe it is becoming increasingly clear that it is a matter of when, not if, federal support of embryonic stem cell research will become reality. According to some polls, roughly two thirds of the American populous is in favor of lifting the restrictions and with the 2008 Presidential election approaching swiftly we believe that change for the better is very near, especially considering the pro-embryonic stem cell research stance of a large number of the leading Presidential candidates. Should the election bring a change in the position of the executive branch, it would remove the last impediment to opening up the floodgate of billions of dollars in federal support for companies like ours.
While a lift on the federal funding ban would certainly benefit our company, our success does not rely solely on such change. In addition to the progress we've made in the current less-favorable environment, there are additional initiatives at the federal level that may benefit Advanced Cell Technology. Most specifically, as discussed above, the NIH announced this year that it would begin implementing President Bush's Executive Order to seek alternative sources of pluripotent stem cell lines, including lines created using our single cell blastomere technology. We are encouraged that our government is seriously considering our technology for funding.
We have also seen continued developments at the state level. Our experiences in California, where our headquarters is located, thus far have been positive including being named this year on a CIRM grant whose recipient will use ACT's human embryonic stem cells to determine if the cells are safe and effective in animal models for heart attacks and heart failure. CIRM funds are finally beginning to get distributed to grant winners. Furthermore, this year CIRM is beginning to award grants to for-profit organizations (like our own) - prior, all of the grants announced had been for non-profit organizations (who can subcontract as much as 50% of the grant to for-profit organizations). New Jersey had proposed a $450 million bond to fund stem cell research that, unfortunately, was defeated; however, we believe the vote was more a reflection of the voters' dissatisfaction with state government spending (New Jersey has a $3 billion budget deficit) rather than a referendum on the ethics and feasibility of stem cell science. In November of this year in Massachusetts, where in 2005 the state's congress overrode and passed a bill, which former-Governor Romney had vetoed, supporting embryonic stem cell research, Governor Deval Patrick proposed a $1 billion stem cell research funding initiative. Also, states including Connecticut, Florida, Illinois, Maryland, New York, and Missouri have passed or proposed similar initiatives. Again, it is our belief that we are nearing the moment when funding for stem cell research will begin to expand. We expect to be a direct beneficiary of the improving climate.
Scientific Developments
This year, scientists including our own as well as researchers outside our company announced a number of regenerative medicine breakthroughs. In addition to our single cell biopsy embryonic stem cell development technique, researchers around the world announced advances such as deriving stem cells from amniotic fluid and skin cells. In January of this year, scientists at Wake Forest University and Harvard University reported that stem cells from amniotic fluid donated by pregnant women may hold promise for pluripotency. We believe the cells may generate a broad range of important cell types, though they may not do as many tricks as embryonic cells. In addition, in November researchers in Japan and the United States announced that they had reprogrammed skin cells to behave like embryonic stem cells. Generating stem cells in this manner has several obstacles to overcome, including dealing with a carcinogenic effect, and likely will not be viable for years to come. Regardless, all of these scientific breakthroughs represent a giant steps forward for stem cell research.
Looking Forward
We expect to enter 2008 on solid footing and look forward to an exciting year. We remain on schedule to begin Phase II human clinical trials for our myoblast adult stem cell therapy for heart failure and are working diligently in preparation for IND filings for our RPE and HG embryonic stem cell therapies for retinal degenerative disorders and heart, blood, and cardiovascular indications, respectively. We are also excited to be seeking international partnerships for each of our clinical and preclinical programs to tap into global market prospects, international scientific expertise, and worldwide non-dilutive financing opportunities. We remain committed, determined, and focused on bringing novel treatments for difficult and impossible to treat indications from the lab to the bedside as well as on returning value to our shareholders.
Wishing you the best for the holiday season and the new year,
William M. Caldwell, IV
Chairman and CEO
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Advanced Cell Technology Awarded Grant from the NIH
Jan 8, 2008 08:00:14 (ET)
LOS ANGELES, Jan 08, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that the National Institute of General Medical Sciences at the National Institutes of Health (NIH) has awarded the company an SBIR Phase 1 Small Business Grant. The company will use the grant proceeds to conduct research that will allow for rapid labeling and purification of specific lineage restricted cells (LRCs) in cultures of differentiating human embryonic stem cells. If successful, the research will help the company more rapidly develop new regenerative therapies for a variety of indications including cardiovascular disease as well for commercialization of the LRCs and their peptide-targeting agents as research reagents. The research aims to create a process by which specific markers can be identified that will act like nametags allowing LRCs to be identified and then purified. With such markers, unique populations of cells can be isolated so that the benefits of these cells can be tested. The research grant from the NIH follows a previous NIH STTR grant award to ACT for a research project from the organization's National Institute for Dental and Craniofacial Research (NIDCR) announced in January 2007.
"We are pleased that prestigious institutions such as the NIH continue to recognize and support our research and development programs," said William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "We will continue to work with the NIH and other organizations to raise awareness and capital to support our ongoing research and commercialization projects without diluting shareholder value. We also remain hopeful that the NIH will ultimately fund our single cell biopsy technique for generating human embryonic stem cell lines without damaging the developmental potential of the embryos."
In August 2006, ACT scientists published a paper in the journal Nature explaining its single-cell biopsy technique for generating hESC lines without destroying the developmental potential of the underlying embryos. In June 2007, the company announced that it had successfully produced such a line. That same month, President Bush issued an Executive Order requiring the Secretary of Health and Human Services to conduct and support research on the isolation of pluripotent stem cells derived without destroying or harming human embryos. In September 2007, the NIH announced that it would begin implementing President Bush's Executive Order and that ACT's single cell biopsy technique was one of the methods under consideration for funding.
"As we've stated before, we believe our single cell biopsy technology directly addresses the President's ethical concerns and, unlike the other potential solutions described in the Executive Order, is available today," continued Mr. Caldwell. "We are encouraged by the NIH's willingness to explore ways to increase the federally approved stem cell lines available. We believe that such consideration reflects the will of the American people to bring novel therapies derived from stem cell research to patients with few or no alternatives.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Investors: CEOcast, Inc. for Advanced Cell Technology, Inc. Daniel Schustack, 212-732-4300 or Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Advanced Cell Technology Announces Creation of Human Embryonic Stem Cell Lines Without the Destruction of Embryos Thursday January 10, 12:00 pm ET -Breakthrough Approach Improves Efficiency to Levels Reported in the Conventional Stem Cell Derivation Techniques-
WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTC Bulletin Board: ACTC - News) together with colleagues announced today the development of five human embryonic stem cell (hESC) lines without the destruction of embryos. These new results have the potential to end the ethical debate surrounding the use of embryos to derive stem cells. In fact, the NIH report to the President refers to this technology as one of the viable alternatives to the destruction of embryos.
ADVERTISEMENT The new method will be published today in the journal Cell Stem Cells, published by Cell Press. The peer-reviewed technique was initially carried out by ACT scientists under the direction of Robert Lanza, M.D., and then independently replicated by scientists on the West Coast. Single cells were removed from the embryos using a technique similar to preimplantation genetic diagnosis (PGD). The biopsied embryos continued to develop normally and were then frozen. The cells that were removed were cultured utilizing a proprietary methodology that recreates the optimal developmental environment, which substantially improved the efficiency of deriving stem cells to rates comparable to using the traditional approach of deriving stem cells from the inner cell mass of a whole blastocyst stage embryo. The stem cells were genetically normal and differentiated into cell types of all three germ layers of the body, including blood cells, neurons, heart cells, cartilage, and other cell types of potentially therapeutic significance.
“This is a working technology that exists here and now,” said Robert Lanza, M.D., Chief Scientific Officer at Advanced Cell Technology and senior author of the paper. “It could be used to increase the number of stem cell lines available to federal researchers immediately. We could send these cells out to researchers tomorrow. If the White House approves this new methodology, researchers could effectively double or triple the number of stem cell lines available within a few months. Too many needless deaths continue to occur while this research is being held up. I hope the President will act now and approve these stem cell lines quickly.”
The paper published today also addresses several other important issues. First, the stem cells were derived without culturing multiple cells from each embryo together, and at efficiency levels similar to that reported for conventional stem cell derivation techniques using blastocysts. Second, it addresses ethical objections that the derivation system required co-culture with hESCs from other embryos that were destroyed. The current study demonstrates that hESC co-culture is not an essential part of the derivation procedure. The stem cell lines generated in the present study appear to have the same characteristics as other hESC lines, including expression of the same markers of pluripotency, self-renewing capacity, genetic stability, and ability to differentiate into derivatives of all three germ layers of the body.
“We are excited that our new method for generating human embryonic stem cell lines without the destruction of embryos has been accepted for inclusion by such a prestigious publication,” said William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology. “This new approach addresses the President Bush’s ethical concerns. We are hopeful that the NIH will consider this new approach for federal funding. We believe that such consideration reflects the desire of the American people to bring therapies derived from stem cell research to patients with few or no alternatives.”
Other contributors to the study and publication include Young Chung and Irina Klimanskaya, Sandy Becker, Tong Li, Marc Maserati, and Shi-Jiang Lu of Advanced Cell Technology; Tamara Zdravkovic, Olga Genbacev, and Susan Fisher of the University of California, San Francisco; and Dusko Ilic and Ana Krtolica of StemLifeLine.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact:
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300 or Cell Stem Cells: Cell Press Cathleen Genova, 617-397-2802
Posts: 3026 | From: Chicago | Registered: Oct 2005
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Coming off bottom like it did I think it did well. NIH is the lead in this imo not ACTC. But actc is taking advantage. I have to learn to just play the TA. The news is spreading and this could have some nice momo in the am - met by convertibles and then an RS that still doesn't have a firm date - so many may not want to hold overnight - and as U said possible dumping. jmo.
like the new Graemlins!!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
FORM 144
NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
ATTENTION: TRANSMIT FOR FILING 3 COPIES OF THIS FORM CONCURRENTLY WITH EITHER PLACING AN ORDER WITH A BROKER TO EXECUTE A SALE OR EXECUTING A SALE DIRECTLY WITH A MARKET MAKER.
-------------------------------------------------------------------------------- ---------------------------------------------------- 1(a) NAME OF ISSUER (Please type or print) (b) IRS IDENT. NO. (c) S.E.C. FILE NO. Advanced Cell Technology 87-0656515
-------------------------------------------------------------------------------- ---------------------------------------------------- (d) ADDRESS OF ISSUER STREET CITY STATE ZIP CODE (e) TELEPHONE NO. ------------------------ 1201 Harbor Bay Parkway Alameda CA 94501 (510) 748-4900
-------------------------------------------------------------------------------- ---------------------------------------------------- 2(a) NAME OF PERSON FOR WHOSE ACCOUNT THE (b) I.R.S. NO. (c) RELATIONSHIP (d) ADDRESS STREET CITY STATE ZIP CODE SECURITIES ARE TO BE SOLD TO ISSUER Bristol Investment Fund, Ltd. 98-0335509 Shareholder Caledonian Fund Services Limited Caledonian House 69 Dr. Roy's Dr. P.O. Box 1043 Grand Cayman KY1-1102 Cayman Islands -------------------------------------------------------------------------------- ---------------------------------------------------- INSTRUCTION: The person filing this notice should contact the issuer to obtain the I.R.S. Identification Number and the SEC File Number -------------------------------------------------------------------------------- ---------------------------------------------------- Name and Address of SEC USE Title of the Class Each Broker Through ONLY of Securities To whom the Securities Are --------- Number of Shares or Aggregate Market Be Sold (See instr. To Be Offered or Each Broker- Other Units To Be Value 3(a)) Market Maker who is Dealer Sold (See instr. 3(d)) Acquiring the Securities File (See instr. 3(c)) (See instr. 3(b)) Number -------------------------------------------------------------------------------- ---------------------------------------------------- Common Stock Citigroup Prime Broker 390 Greenwich Street, 3rd Floor 177,937 $44,484 New York, NY 10013 -------------------------------------------------------------------------------- ----------------------------------------------------
Number of Shares or Approximate Date of Name of Each Securities Other Units Sale Exchange Outstanding (See instr. 3(f)) (See instr. 3(g)) (See instr. (MO. DAY YR.) 3(e)) -------------------------------------------------------------------------------- ---------------------------------------------------- 81,333,064 1/10/2008 OTC BB -------------------------------------------------------------------------------- ----------------------------------------------------
INSTRUCTIONS: 1. (a) Name of issuer. (b) Issuer's IRS Identification Number. (c) Issuer's SEC file number, if any. (d) Issuer's address, including zip code. (e) Issuer's telephone number, including area code.
2. (a) Name of person for whose account the securities are to be sold. (b) Such person's or I.R.S. Identification number, if such a person is an entity. (c) Such person's relationship to the issuer (e.g., officer, director, 10 percent stockholder, or member of immediate family of any of the foregoing). (d) Such person's address, including zip code.
3. (a) Title of the class of securities to be sold (b) Name and address of each broker through whom the securities are intended to be sold. (c) Number of shares or other units to be sold (if debt securities, give the aggregate face amount). (d) Aggregate market value of the securities to be sold as of a specified date within 10 days prior to the filing of this notice. (e) Number of shares or other units of the class outstanding, or if debt securities the face amount thereof outstanding, as shown by the most recent report or statement published by the issuer. (f) Approximate date on which the securities are to be sold. (g) Name of each securities exchange, if any, on which the securities are intended to be sold.
Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:
-------------------------------------------------------------------------------- ---------------------------------------------------- Title of Date You Nature of Acquisition Name of Person From Amount of Date of Nature of Payment the Class Acquired Transaction Whom Acquired Securities Payment (If Gift, Also Give Acquired Date Donor Acquired) -------------------------------------------------------------------------------- ---------------------------------------------------- Common Stock 9/6/06 Convertible Note Issuer 177,937 9/6/06 Cash
INSTRUCTIONS: 1. If the securities were purchased and full payment therefore was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid. 2. If within two years after the acquisition of the securities the person for whose account they are to be sold had any short positions, put or other option to dispose of securities referred to in paragraph (d)(3) of Rule 144, furnish full information with respect thereto.
TABLE II--SECURITIES SOLD DURING THE PAST THREE MONTHS
Furnish The Following Information as to All Securities of The Issuer Sold During The Past Three Months By The Person For Whose Account The Securities Are To Be Sold.
-------------------------------------------------------------------------------- ---------------------------------------------------- Name and Address of Seller Title of Securities Sold Date of Sale Amount of Gross Proceeds Securities Sold -------------------------------------------------------------------------------- ---------------------------------------------------- Caledonian Fund Services Limited Caledonian House 69 Dr. Roy's Drive P.O. Box 1043 Grand Cayman KY1-1102 Cayman Islands Advanced Cell Technology, Inc. 11/16/2007 20,000 $4,033 Advanced Cell Technology, Inc. 11/19/2007 20,000 $3,927 Advanced Cell Technology, Inc. 11/20/2007 20,000 $4,033 Advanced Cell Technology, Inc. 11/21/2007 102,937 $27,248 Advanced Cell Technology, Inc. 11/21/2007 15,000 $3,961 Advanced Cell Technology, Inc. 12/10/2007 135,000 $28,995 Advanced Cell Technology, Inc. 12/12/2007 70,000 $14,010 Advanced Cell Technology, Inc. 12/17/2007 20,000 $3,840 Advanced Cell Technology, Inc. 12/20/2007 59,699 $10,089
INSTRUCTIONS: See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice. January 10, 2008 ---------------------------------------- (DATE OF NOTICE) ATTENTION: The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the issuer of the securities to be sold which has not been publicly disclosed. /s/ Paul Kessler ---------------------------------------- (SIGNATURE)
The notice shall be signed by the persons for whose account the securities are to be sold. At least one copy of the notice shall be manually signed. Any copies not manually signed shall bear typed or printed signatures.
ATTENTION: INTERNATIONAL MISSTATEMENTS OR OMISSION OF FACTS CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Caledonian Fund Services Limited Caledonian House 69 Dr. Roy's Drive P.O. Box 1043 Grand Cayman KY1-1102 Cayman Islands
Very interesting indeed.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
This proxy, when properly executed, will be voted in the manner directed herein by the undersigned stockholder. If no direction is given, this proxy will be voted FOR the proposal to increase the number of shares issuable under the Company's 2005 Stock Incentive Plan by 25,000,000. Attendance of the undersigned at the Meeting will not be deemed to revoke this proxy unless the undersigned shall revoke this proxy in writing or shall deliver a subsequently dated proxy to the Secretary of the Company or shall vote in person at the Meeting.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
Beacon Research's TraderNotes are brief analyses on the active stocks each day that are affecting the markets. These include breaking news, insider activity, recent 52-week highs/lows, technical breakouts, and other market driving information. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquityResearch.com -- Click on TraderNotes
Beacon Equity Research is one of the industry's largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquityResearch.com CRD# 1755680
Beacon Equity Research Disclosure
The companies that are discussed have not always approved the statements made in this opinion. These reports are for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell any securities mentioned. We are not a licensed or registered broker dealer, investment advisor, analyst or underwriter. Please consult a registered broker before purchasing or selling any securities viewed or mentioned here. Beacon Equity Research has not been compensated by any of the companies covered in this release.
Beacon Equity Research Jeff Bishop, (469)-252-3505 press*beaconequityresearch.com
Reuben Sushman of Beacon Equity Research is a member of the National Association of Securities Dealers, CRD number 1755680.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. JEFF BISHOP
quote:Originally posted by T e x: What else is Bristol into?
I have found quite a bit out there Tex. Another Steve Carnes??? Still researching.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Universal Communication Systems Inc • SB-2/A • On 7/13/06
(5) Bristol Capital Advisors, LLC is the investment adviser to Bristol Investment Fund, Ltd. Paul Kessler is the manager of Bristol Capital Advisors and, accordingly, may be deemed to have voting and investment control over these securities. Mr. Kessler disclaims beneficial ownership of these securities.
Bristol Investment Fund, Ltd. (5) Caledonian Fund Services Limited 69 Dr. Roy’s Drive George Town, Grand Cayman Cayman Islands N/A 156,626,600(2) 30.67% 156,626,600(2) 0%
This is just for starters - Don't want to trash ACTC but some of the action over the last few days is from the major pumping and dumping - not all from Kessler imo.
a couple others - just search results - haven't had a chance to convert to current charts and data. Nabi Biopharmaceuticals JAWS Technologies EPICEPT CORP ADVANCED MAMMOGRAPHY SYSTEMS, INC.
There are plenty more - is there a simple way to find out just how many companies someone is holding major shares? lol
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Cool]](cool.gif)
![[Wink]](wink.gif)
![[Good Luck]](graemlins/goodluck.gif)
![[Big Grin]](biggrin.gif)
![[Were Up]](graemlins/wereup.gif)
![[Smile]](smile.gif)
